文献速递炎症性肠病

住院IBD患者静脉阿片暴露与出院后阿片处方相关

Exposure to Intravenous Opioids Is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-27

一项回顾性队列研究纳入862例住院IBD成人,评估住院期间静脉阿片暴露与出院后12个月内阿片处方的关联。多因素混合效应逻辑回归显示,静脉阿片暴露与出院后阿片处方显著相关(OR 3.3,95%CI 1.7-6.4),且呈剂量依赖效应。

要点

  • 住院IBD患者静脉阿片暴露与出院后12个月内阿片处方显著相关(OR 3.3)。
  • IBD flare亚组中关联更强(OR 5.4),静脉阿片剂量(IVMMEs/天)也显示关联。
  • 未用静脉阿片者中,口服/透皮阿片仍与出院后阿片处方相关(OR 4.2)。

核心结论

  • 住院期间静脉和非静脉阿片使用均与IBD患者出院后阿片暴露相关,且呈剂量依赖效应。

研究设计与样本

  • 回顾性队列研究,纳入2017年3月1日至2018年4月10日在一家大型城市学术医疗系统住院的862例IBD成人。
  • 使用电子健康记录数据,采用多因素混合效应逻辑回归分析住院阿片暴露与出院后12个月内阿片处方的关联。

主要发现

  • 静脉阿片 vs 无静脉阿片与出院后阿片处方的OR为3.3(95%CI 1.7-6.4)。
  • 静脉阿片剂量(IVMMEs/天)的OR为1.1(95%CI 1.0-1.1)。
  • IBD flare亚组(n=621)中,静脉阿片 vs 无静脉阿片的OR为5.4(95%CI 2.6-11.0)。
  • 未用静脉阿片者中,口服/透皮阿片 vs 无阿片的OR为4.2(95%CI 1.0-16.8)。

临床怎么用

  • 对住院IBD患者应考虑替代镇痛药,以减少未来阿片使用风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Opioid use is associated with increased mortality in patients with inflammatory bowel diseases (IBD). Hospitalized patients with IBD often receive high-potency intravenous opioids (IVOPIs). It is not known whether exposure to IVOPIs affects post-discharge opioid use or complications. We investigated the association between inpatient administration of IVOPIs and a post-discharge opioid prescription (OPIRx) in patients with IBD. METHODS: We performed a retrospective cohort study of 862 adults with IBD hospitalized at a large urban academic health system from March 1, 2017 through April 10, 2018. We collected clinical data from the electronic health records and used multivariable mixed-effect logistic regression to assess the association between inpatient opioid exposure and OPIRx-within 12 months while adjusting for confounders. IV and non-IVOPI exposures were evaluated as binary variables. IVOPI exposure was also evaluated as a continuous variable in IV morphine mg equivalents/length of stay (IVMMEs/day). RESULTS: Multivariable mixed-effect logistic regression demonstrated a significant association between IVOPIs and OPIRx (IV vs no IVOPIs odds ratio [OR], 3.3; 95% CI, 1.7-6.4 and IVMMEs/day OR, 1.1; 95% CI, 1.0-1.1). Subgroup analysis of patients with IBD flares (n = 621) identified a significant association between IVOPIs and OPIRx (IV vs no IVOPIs OR, 5.4; 95% CI, 2.6-11.0). Among patients who did not receive IVOPIs, there was a significant association between oral/transdermal opioids and OPIRx (non-IVOPIs vs no opioids OR, 4.2; 95% CI, 1.0-16.8). CONCLUSIONS: Inpatient IV and non-IV opioid use are associated with post-discharge opioid exposure in patients with IBD, with a dose-dependent effect. Alternative analgesics should be considered for hospitalized patients with IBD, to minimize risk of future opioid use.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dalal RS, Palchaudhuri S, Snider CK, et al. Exposure to Intravenous Opioids Is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019. PMID: 31887450. doi:10.1016/j.cgh.2019.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。